2. Academic Validation
  3. Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming

Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming

  • Transl Oncol. 2025 Apr:54:102327. doi: 10.1016/j.tranon.2025.102327.
Yu Li 1,  Yifan Jiang 1,  Rongliang Tong 1,  Bo Ding 1,  Jiangzhen Ge 1,  Keyi Du 1,  Jingqi Sun 1,  Zheng Tang 2,  Diyu Chen 3,  Jian Wu 4
Affiliations

Affiliations

  • 1 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, PR China; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, PR China; Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences, Hangzhou, 310003, PR China; Key Laboratory of Organ Transplantation, Zhejiang province, Hangzhou, 310003, PR China.
  • 2 Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, PR China.
  • 3 Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, PR China. Electronic address: 21618112@zju.edu.cn.
  • 4 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, PR China; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, PR China; Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences, Hangzhou, 310003, PR China; Key Laboratory of Organ Transplantation, Zhejiang province, Hangzhou, 310003, PR China. Electronic address: drwujian@zju.edu.cn.
PMID: 39986191 DOI: 10.1016/j.tranon.2025.102327
Abstract

Intrahepatic cholangiocarcinoma (ICC) is an aggressive Cancer with an extremely poor prognosis, highlighting the urgent need for new treatment options. Recent studies increasingly suggest that the Forkhead box M1 (FOXM1) transcription factor may serve as a candidate target for Cancer Immunotherapy. However, its role and the underlying molecular mechanisms in ICC remain not fully understood. Here, we identify thiostrepton (TST) as a potent FOXM1 inhibitor, capable of exerting "dual anti-tumor" effects in ICC. On one hand, TST effectively suppresses tumor cell proliferation and metastasis. On the Other hand, TST treatment improves the tumor immune microenvironment by reprogramming tumor-associated macrophages (TAMs), thereby enhancing anti-tumor immune responses. Mechanistically, TST directly alleviates ICC progression by arresting the cell cycle, promoting Apoptosis, and inhibiting the epithelial-mesenchymal transition (EMT) process. Furthermore, TST-treated tumor cells secrete cytokines that drive TAMs repolarization toward the tumor-suppressive M1 phenotype. Overall, our results indicate that FOXM1 can serve as a novel target for ICC immunotherapy. By targeting FOXM1, TST exerts "dual anti-tumor" effects and has the potential to become a promising immunotherapy agent for ICC patients.

Keywords

Forkhead box M1; Immunotherapy; Intrahepatic cholangiocarcinoma; Thiostrepton; Tumor-associated macrophages.

Figures
Products